난치성 위식도역류질환의 원인 및 치료 = Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease

다국어 초록 (Multilingual Abstract)

The prevalence of gastroesophageal reflux disease (GERD) in South Korea has increased over the past 10 years. Patients with erosive reflux disease (ERD) shows better response to proton pump inhibitors (PPIs) than those with non-erosive reflux disease (NERD). NERD is a heterogeneous condition, showing pathological gastroesophageal reflux or esophageal hypersensitivity to reflux contents. NERD patients with pathological gastroesophageal reflux or hypersensitivity to acid may respond to PPIs.
However, many patients with esophageal hypersensitivity to nonacid or functional heartburn do not respond to PPIs. Therefore, careful history and investigations are required when managing patients with refractory GERD who show poor response to conventional dose PPIs. Combined pH-impedance studies and a PPI diagnostic trial are recommended to reveal underlying mechanisms of refractory symptoms. For those with ongoing reflux-related symptoms, split dose administration, change to long-acting PPIs or PPIs less influenced by CYP2C19 genotypes, increasing dose of PPIs, and the addition of alginate preparations, prokinetics, selective serotonin reuptake inhibitors, or tricyclic antidepressants can be considered. Pain modulators, selective serotonin reuptake inhibitors, or tricyclic antidepressants are more likely to be effective for those with reflux-unrelated symptoms.
Surgery or endoscopic per oral fundoplication may be effective in selected patients.

참고문헌 (Reference)

1 정혜경, "위식도역류질환 임상진료지침 개정안 2012" 대한소화기학회 60 (60): 195-218, 2012

2 Kahrilas PJ, "The acid pocket: a target for treatment in reflux disease?" 108 : 1058-1064, 2013

3 김정환, "Recent Advances in Noncardiac Chest Pain in Korea" 거트앤리버 발행위원회 6 (6): 1-9, 2012

4 Hatlebakk JG, "Proton pump inhibitors : better acid suppression when taken before a meal than without a meal" 14 : 1267-1272, 2000

5 Lee D, "Prevalence of asymptomatic erosive esophagitis and factors associated with symptom presentation of erosive esophagitis" 48 : 906-912, 2013

6 Lee SY, "Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study" 79 : 196-201, 2009

7 Cho YS, "Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea" 100 : 747-753, 2005

8 김성은, "Predictive Factors of Response to Proton Pump Inhibitors in Korean Patients With Gastroesophageal Reflux Disease" 대한소화기 기능성질환∙운동학회 21 (21): 69-77, 2015

9 Scarpignato C, "Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!" 24 : 697-704, 2012

10 Yamada S, "Genetic differences in CYP2C19single nucleotide polymorphisms among four Asian populations" 36 : 669-672, 2001

11 Savarino V, "Functional heartburn and non-erosive reflux disease" 25 : 172-174, 2007

12 Hammer J, "Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough" 19 : 1105-1110, 2004

13 Lee KJ, "Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group" 79 : 131-136, 2009

14 Sugimoto M, "Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese" 70 : 1073-1078, 2014

15 박효진, "An Overview of Eosinophilic Esophagitis" 거트앤리버 발행위원회 8 (8): 590-597, 2014

16 김은경, "Achalasia in Korea: An Epidemiologic Study Using a National Healthcare Database" 대한의학회 29 (29): 576-580, 2014